Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.81 |
| ▸ | FNTA | P49354 | 7/20 | 0.41 |
| ▸ | FNTB | P49356 | 7/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14434342 | 0.90 | TACR1 (1.00) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL8460496 | 0.90 | TACR1 (1.00) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL4349316 | 0.90 | TACR1 (1.00) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL7551020 | 0.90 | TACR1 (1.00) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL29373792 | 0.90 | TACR1 (1.00) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL9729727 | 0.82 | TACR1 (0.82) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL9729517 | 0.80 | TACR1 (0.71) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL9729596 | 0.79 | TACR1 (0.80) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL9729430 | 0.79 | TACR1 (0.80) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL9731121 | 0.79 | TACR1 (0.73) | TACR1MEN1KMT2ACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885MEN1 1273/4885KMT2A 3242/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885MEN1 1273/4885KMT2A 3242/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885MEN1 1273/4885KMT2A 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.